The cells responsible for bone remodeling, highlighting key signaling pathways that are targets
for therapies recommended for the prevention of osteoporotic fracture.
Notes: Osteocytes are embedded within mineralized bone and, in response to
mechanical loading or microdamage, provide signals to osteoclasts to resorb. Osteoclast
differentiation and function is dependent on the RANKL–RANK signaling pathway, which in
vivo, is negatively regulated by OPG. Circulating PTH is a physiological regulator of plasma calcium
and binds to PTHR on osteoblasts to indirectly stimulate osteoclast activity via upregulation of
RANKL and downregulation of OPG expression. Calcitonin binds to the CTR expressed on mature
osteoclasts to reversibly inhibit osteoclast function, although the exact physiological relevance
for calcitonin is not fully understood. E2 has a positive effect on bone, through effects
on osteoblasts and osteoclasts via ERα. CatK is secreted by resorbing osteoclasts across the
convoluted ruffled border membrane and is required to degrade collagen. Osteoclast activity releases
factors from the bone, which attract osteoblasts to the site of resorption. Osteoblast
differentiation and function is controlled by the Wnt signaling pathway via the LRP5/6 and Frizzled
co-receptors, which is regulated by endogenous inhibitors such as sclerostin, expressed by
osteocytes and upregulated in response to unloading.
Abbreviations: CatK, cathepsin K; CTR, calcitonin receptor; E2, estrogen;
ERα, estrogen receptor; LRP5/6, lipoprotein-related protein 5/6; OPG, osteoprotegerin; PTH,
parathyroid hormone; PTHR, PTH receptor; RANK, receptor activator of nuclear factor-κB;
RANKL, RANK ligand.